Oppenheimer analyst Leland Gershell initiated coverage with a Buy rating on ADMA Biologics (NASDAQ: ADMA) today and set a price target of $13. The company’s shares opened today at $4.42.
Gershell commented:
“We are initiating coverage on ADMA with an Outperform rating and a 12-18 month $13 PT. We see ADMA as an early turnaround story that is set for stock outperformance heading into 2H18 catalysts and beyond. Following third-party manufacturing plant issues that had held up approval of its lead IV immunoglobulin (IVIG) candidate since late 2015, in our opinion ADMA has not only adequately addressed these items but has also built itself into a fully-integrated biopharmaceutical company by gaining control of the facility through a strategic transaction. Although shares are up ~40% YTD as ADMA has made admirable progress, we believe the market has trailed the company’s strengthening fundamentals due to a lack of regulatory visibility, providing an attractive opportunity for investors.”
According to TipRanks.com, Gershell is ranked 0 out of 5 stars with an average return of -30.8% and a 0.0% success rate. Gershell covers the Healthcare sector, focusing on stocks such as Avenue Therapeutics Inc, Evofem Biosciences Inc, and Urogen Pharma Ltd.
ADMA Biologics has an analyst consensus of Moderate Buy, with a price target consensus of $8.75.
See today’s analyst top recommended stocks >>
The company has a one-year high of $5.70 and a one-year low of $2.01. Currently, ADMA Biologics has an average volume of 225.8K.
Based on the recent corporate insider activity of 14 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of ADMA in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
ADMA Biologics, Inc. is a biopharmaceutical company. It develops, manufactures, and intends to commercialize in human plasma and plasma-derived therapeutics. It operates through the following business segments: ADMA BioManufacturing, Plasma Collection Center, and Corporate.
